MedTrace Logo

URACYST® For the Treatment of GAG Deficient Interstitial Cystitis

NCT00150488 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2023-07-27

Study results available
· View outcomes & findings →

Summary

This protocol describes a multi-centre, community based open label study designed to assess the efficacy and safety of intravesical sodium chrondroitin sulfate (Uracyst®) in the treatment of patients with a clinical diagnosis of interstitial cystitis (IC).

The safety of the study product will be evaluated through the incidence of adverse events and from results of physical examinations and laboratory tests.

Conditions

  • Painful Bladder Syndrome
  • Interstitial Cystitis

Interventions

DEVICE

Uracyst

2% weekly for 6 weeks, monthly for 4 months

Sponsors & Collaborators

  • Stellar Pharmaceuticals

    collaborator INDUSTRY

  • Dr. J. Curtis Nickel

    lead OTHER

Principal Investigators

  • Curtis Nickel, MD FRCSC · Queen's University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2008-01-31
Completion
2008-02-29

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00150488 on ClinicalTrials.gov